Type 2 Diabetes
New findings from Juntendo University, Medical Department describe advances in type 2 diabetes
Published in Obesity and Diabetes Week, October 5th, 2009
In this recent article published in the journal Diabetes Obesity & Metabolism, scientists in Hongo, Japan conducted a study "To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs (OAD; sulphonylurea or sulphonylurea + biguanide) relative to that of OAD alone in Japanese and Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM). In an open, randomized, parallel-group, comparative, controlled trial, 387 patients were randomized and treated with glulisine + OAD (n = 130), glulisine monotherapy (n = 127) or OAD only (n = 130) for 16 weeks."
"Glulisine was self-injected subcutaneously...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Apnea-hypopnea Syndrome
Research data from M. Murri and colleagues update understanding of apnea-hypopnea syndrome - Bariatrics
Study data from University of Athens provide new insights into bariatrics - Diabetes
Report summarizes diabetes study findings from University of Texas - Dialysis
New dialysis research from National Taiwan University described - Heart Disease
Studies from Brigham and Women's Hospital yield new data on heart disease - Insulin Resistance
Studies conducted at University of Pittsburgh on insulin resistance recently published - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
